Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 10/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2476617 | 0.89 | MEN1 (0.40) | MEN1KMT2AALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL27329418 | 0.87 | PKM (0.45) | CYP4F2CYP4A11USP2SMN1; SMN2 | |
| SCHEMBL2474730 | 0.87 | USP2 (0.40) | MEN1KMT2AALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL415499 | 0.87 | MEN1 (0.42) | MEN1KMT2AALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL6187331 | 0.86 | CYP4F2 (0.46) | MEN1KMT2AALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL7443750 | 0.85 | CYP4F2 (0.45) | MEN1KMT2AALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL6186611 | 0.85 | MEN1 (0.41) | MEN1KMT2AALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL1440150 | 0.85 | MEN1 (0.41) | MEN1KMT2AALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL963907 | 0.84 | USP2 (0.47) | MEN1KMT2AALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL2795230 | 0.84 | CYP4F2 (0.53) | MEN1KMT2AALDH1A1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533995-B2 | Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof | SANOFI (FR) | 2017-01-03 | — | — | US | disclosed |
| US-9533995-B2 | Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof | SANOFI (FR) | 2017-01-03 | — | — | US | disclosed |
| US-9453023-B2 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| US-9453023-B2 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| US-9453023-B2 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| EP-2569280-B1 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI SA (FR) | 2015-02-25 | — | — | EP | disclosed |
| EP-2569280-B1 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI SA (FR) | 2015-02-25 | — | — | EP | disclosed |
| US-20140315923-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-10-23 | — | — | US | disclosed |
| US-20140315923-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-10-23 | — | — | US | disclosed |
| US-20140315923-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-10-23 | — | — | US | disclosed |
| WO-2011143148-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143150-A1 | SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143148-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143150-A1 | SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | disclosed |
| US-20110257213-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-20 | — | — | US | disclosed |
| US-20110257213-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-20 | — | — | US | disclosed |
| US-20110257213-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-20 | — | — | US | disclosed |
| EP-2373652-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONES USED AS H3 MODULATORS | SANOFI (FR) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010065803-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONES USED AS H3 MODULATORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065803-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONES USED AS H3 MODULATORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257213-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | HRH3, HRH4, PRLHR | MEN1 2118/4885KMT2A 457/4885ALDH1A1 696/4885 |
| US-20140315923-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | CHRM2, NR3C2, NPSR1 | MEN1 2415/4885KMT2A 732/4885ALDH1A1 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.